CDK9 is a transcriptional kinase that functions as the catalytic component of the P-TEFb (positive transcription elongation factor b) complex, which facilitates productive RNA polymerase II elongation by phosphorylating RNAPII CTD at Ser-2 123. CDK9 phosphorylates multiple substrates including negative elongation factors DSIF and NELF to promote transcription 45, and regulates histone modifications including H2B monoubiquitination and H3K4me3 to coordinate chr9 remodeling with transcription 67. CDK9 integrates cytokine signaling by facilitating TNF and IL-6-inducible transcription factor activation 89. Clinically, CDK9 inhibition shows promise across multiple cancer types. Selective CDK9 inhibitors like AZD4573 induce rapid apoptosis in hematologic malignancies by depleting MCL-1 10, while CDK9 degradation via PROTACs demonstrates prolonged cytotoxic effects compared to kinase inhibition 11. In hepatocellular carcinoma, CDK9 inhibition blocks mitophagy and enhances mitochondrial dysfunction 12, while in cutaneous T-cell lymphoma, CDK9 inhibition combined with ATRA shows synergistic activity 13. PP2A-mediated antagonism of CDK9 phosphorylation provides additional therapeutic opportunity 14, and CDK9 function in CD8+ T cell immunity impacts immunotherapy response 15.